The Long-Term Risks of Mounjaro: Separating Evidence from Anxiety

The biggest misconception: 'Not enough is known about Mounjaro to take it safely'

This is the thought that stops a lot of people, and it deserves a straight answer rather than reassurance for its own sake. Tirzepatide is not brand new to science. SURMOUNT-1, the pivotal weight-management trial, ran for 72 weeks and randomised 2,539 adults; the broader SURMOUNT and SURPASS programme across weight management and type 2 diabetes involved over 10,000 participants in total before the UK licence was granted. The MHRA reviewed all of that before approving Mounjaro for weight management. NICE went through it again before publishing TA1026 in December 2024.

That said, 'enough data to grant a licence' is not the same as 'decades of population-level evidence'. The Black Triangle status is the MHRA's honest acknowledgement of that gap: it signals continued active surveillance, not a red flag. For most people whose prescriber judges the benefits to outweigh the risks, that is a reasonable trade-off, particularly given the well-documented health consequences of untreated obesity. If you are weighing up whether Mounjaro is safe to take long term, the key is that the decision is made with clinical oversight, not around it.

Side effects that can appear over months of treatment

Most of the reported side effects are gastrointestinal: nausea, loose stools, constipation, indigestion, and (yes) the sulphurous burping that some people find more socially disruptive than the nausea itself. The smell and cause of Mounjaro-related burping is largely a consequence of slowed gastric emptying, and it tends to ease as the body adjusts. These effects are most pronounced in the first weeks at a new dose and usually settle.

Over a longer treatment course, a few patterns merit attention. Muscle loss alongside fat loss is a recognised concern with any significant calorie deficit; adequate protein intake and resistance activity are consistently recommended alongside treatment. Gallbladder problems, including gallstones, have been reported with GLP-1 and dual-agonist medicines, rapid weight loss itself is a known gallstone risk factor. Hair thinning (telogen effluvium) can occur when the body is under caloric stress; it typically reverses once weight stabilises. Anyone wanting a fuller picture can find detail on what the long-term side effects of Mounjaro may include, alongside the NHS medicines page for tirzepatide, which lists reported effects with plain-language guidance on what to do about each one.

Lean body mass can be preserved with the right lifestyle support, one reason our prescribers discuss diet and activity as part of every assessment, not as an afterthought.

When to get medical help, and what can't wait

Most side effects are uncomfortable rather than dangerous. A few signals require prompt medical attention. Severe, persistent abdominal pain that spreads toward the back (with or without vomiting) should be treated as a potential sign of acute pancreatitis and warrants urgent assessment. The MHRA highlighted this specifically in its Drug Safety Update of January 2026, not to alarm patients but to ensure they don't wait it out at home.

Symptoms suggesting dehydration from prolonged vomiting or diarrhoea (dizziness, reduced urination, feeling faint) need attention before they cascade into a kidney problem. Signs of a serious allergic reaction (throat tightening, swelling of the face or lips, severe rash) require emergency help. If you notice rapid heartbeat, neck lumps, or changes in vision during treatment, contact your prescriber promptly rather than waiting for a routine review.

Keep the Patient Information Leaflet that comes with your pen somewhere accessible (the fridge door where you store the pen is an obvious spot) because the full list of signs and severity thresholds is there in detail the body copy of any website shouldn't replicate. If you're ever unsure, calling 111 or contacting our team via the support page are both reasonable first steps.

What longer-term use means in practice, and how prescribers manage it

Tirzepatide is licensed for ongoing weight management, not as a short course. That means prescribers must review the benefit-risk balance at intervals, not just at initiation. NICE guidance states that if less than 5% weight loss is achieved after six months at the highest tolerated dose, the decision to continue should be reconsidered, a built-in checkpoint rather than open-ended prescribing. You can read more about how that framework applies in the broader context of tirzepatide long-term risks.

Thyroid concerns are sometimes raised, rodent studies showed C-cell tumours with GLP-1 medicines at very high doses, but this has not been replicated in human trials or post-marketing data. It remains a precaution rather than an established human risk: people with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome are excluded from treatment, and prescribers ask about this at assessment. A full discussion of Mounjaro's risk profile covers these cautions in more depth.

For most people assessed as suitable, the evidence currently supports continued treatment under clinical supervision as safer than the health risks associated with significant obesity. Whether that applies to you is exactly the kind of question our prescribers work through as part of the consultation, and if you'd like to explore that, checking your eligibility is the place to start.